A multicenter, randomized, open-labelled, non-inferiority trial of sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery intervention

Han, Ahram; Lee, Taeseung; Lee, Joongyub; Song, Suk-Won; Lee, Sang Su; Jung, In Mok; Kang, Jin Mo; Gwon, Jun Gyo; Yun, Woo‐Sung; Cho, Yong‐Pil; Ko, Hyunmin; Park, Yang-Jin; Min, Seung-Kee

doi:10.1038/s41598-023-29006-z

Cited by 2 publications

(1 citation statement)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sarpogrelate has been widely used in treating cardiovascular disorders via specifically antagonizing 5-HT2A receptor signaling (153). Thus, to investigate the role of 5-HT2A receptor in serotoninmediated deterioration that caused pulmonary capillary leakage in humanized mice, sarpogrelate was employed (84).…”

Section: Targeting Platelet Activationmentioning

confidence: 99%

Update on transfusion-related acute lung injury: an overview of its pathogenesis and management

Lian

2023

Front. Immunol.

View full text Add to dashboard Cite

Transfusion-related acute lung injury (TRALI) is a severe adverse event and a leading cause of transfusion-associated death. Its poor associated prognosis is due, in large part, to the current dearth of effective therapeutic strategies. Hence, an urgent need exists for effective management strategies for the prevention and treatment of associated lung edema. Recently, various preclinical and clinical studies have advanced the current knowledge regarding TRALI pathogenesis. In fact, the application of this knowledge to patient management has successfully decreased TRALI-associated morbidity. This article reviews the most relevant data and recent progress related to TRALI pathogenesis. Based on the existing two-hit theory, a novel three-step pathogenesis model composed of a priming step, pulmonary reaction, and effector phase is postulated to explain the process of TRALI. TRALI pathogenesis stage-specific management strategies based on clinical studies and preclinical models are summarized with an explication of their models of prevention and experimental drugs. The primary aim of this review is to provide useful insights regarding the underlying pathogenesis of TRALI to inform the development of preventive or therapeutic alternatives.

show abstract

Section: Targeting Platelet Activationmentioning

confidence: 99%

Update on transfusion-related acute lung injury: an overview of its pathogenesis and management

Lian

2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Comparison of efficacy and safety of sarpogrelate-based anti-platelet therapy with clopidogrel-based anti-platelet therapy following arterial endovascular therapy: A systematic review

Kaur Jhajj,

Razick,

Batea Khaleefah

et al. 2024

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

Objective: Sarpogrelate is a selective serotonin/5-hydroxytryptamine 2A receptor antagonist used in the management of peripheral artery disease (PAD). The drug has emerged as a promising choice for medical management post-endovascular therapy (EVT) due to its anti-platelet aggregation, vasoconstriction, and anti-vascular smooth muscle proliferation properties. The aim of the meta-analysis is to evaluate the efficacy and safety of sarpogrelate-based APT following arterial EVTs in PAD. Material and Methods: PubMed, Google Scholar, Scopus, and the Cochrane were systematically searched from inception to December 2023. Any randomized controlled trial studies in English that evaluated the efficacy and safety of sarpogrelate-based APT after EVT in patients with PAD was included. Data on the restenosis rate, target lesion revascularization (TLR), and safety parameters were extracted and studied. The pooled differences in efficacy and safety parameters between sarpogrelate-based APT and non-sarpogrelate-based APT was calculated using the relative risk (RR) with a 95% CI. Results: A total of three randomized controlled trials were included out of 354 articles obtained through a literature search. No significant differences were observed in the risk of restenosis (RR=0.74, 95% C.I.= 0.55- 1.00, P=0.954) and TLR (RR=0.76, 95% C.I.= 0.47- 1.23 , P=0.476) among patients being treated with sarpogrelate and non-sarpogrelate based APT. Likewise, sarpogrelate-based APT had similar safety profile as non-sarpogrelate-based APT. Conclusion: Sarpogrelate-based APT can be considered an effective alternative to clopidogrel-based conventional APT after EVTs. However, there is a huge need for a larger multicenter, multinational, and multiethnic global trial with sufficient participants in order to produce generalizable findings.

show abstract

A multicenter, randomized, open-labelled, non-inferiority trial of sustained-release sarpogrelate versus clopidogrel after femoropopliteal artery intervention

Cited by 2 publications

References 33 publications

Update on transfusion-related acute lung injury: an overview of its pathogenesis and management

Update on transfusion-related acute lung injury: an overview of its pathogenesis and management

Comparison of efficacy and safety of sarpogrelate-based anti-platelet therapy with clopidogrel-based anti-platelet therapy following arterial endovascular therapy: A systematic review

Contact Info

Product

Resources

About